UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
NHS
CompanyAlso known as: NHS
Related News
UK Approves First GLP-1 Weight Loss Tablet as Semaglutide Landscape Shifts
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
EMA Bolsters Clinical Trial Transparency and Launches Vaccine Information Drive
The European Medicines Agency is enforcing clinical trial transparency and has launched a new vaccine information initiative, while a coalition of health professionals warns of suboptimal vaccination coverage across Europe. An analysis also shows that only a portion of EMA-approved medicines are available to NHS patients in England after additional assessments.
England to Screen All Newborns for SMA After Jesy Nelson Campaign; Real-World Zolgensma Data Show Motor Gains
England will screen all newborns for SMA after Jesy Nelson's campaign. A real-world study found Zolgensma helped children with SMA achieve motor milestones, with newborn screening leading to earlier gains.
UK Biotech Funding Falls 49% as Sector Struggles to Scale Despite Industrial Strategy Priority
UK biotech equity financing fell 49% in 2025, leading to calls for a £500m pension fund injection. The UK hosts over half of Europe's advanced therapy trials, yet risks losing its life sciences status to international competition.
Measles Outbreaks Hit Highest Levels in Decades; Utah Leads with 499 Cases in 2026
Measles cases in the U.S. reached 2,288 in 2025, the highest since 1992, with 2,104 cases reported in the first half of 2026. Utah has seen 499 cases this year, more than 20% of the national total, driven by pockets of low vaccination. Health officials emphasize vaccination and early symptom recognition to prevent spread.
NHS-Galleri Trial Misses Primary Endpoint but Shows 26% Reduction in Stage IV Cancer by Third Round
The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.
NICE Updates Type 2 Diabetes Guidance for Earlier SGLT-2 Inhibitor Use; SGLT2 Inhibitors Also Linked to Survival Benefit in Takotsubo Syndrome
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
Support for sharing health data for AI hinges on safeguards, consent and public benefit
A U.K. focus-group study found support for sharing health data for AI is conditional on public benefit, safeguards and meaningful consent. The findings come as Europe tightens control over biomedical datasets under data-sovereignty policies.
Real-World Data Market Forecast to Reach $4.21 Billion by 2030
The real-world data market is projected to grow from $2.34 billion in 2026 to $4.21 billion by 2030. Growth is driven by EHR adoption, regulatory acceptance of real-world evidence, and AI-driven analytics.